Cutaneous squamous cell carcinoma (cSCC) of the skin is the second most common form of skin cancer, with aging and prolonged exposure to ultraviolet rays being the main causes of the disease. Cemiplimab and pembrolizumab recently gained regulatory approval for the treatment of locally advanced and metastatic cSCC—conditions that are not treatable by surgical resection and/or radiotherapy. Although the results from the clinical trials have been promising, these studies have not included immunosuppressed, elderly patients. In this study, we included all immunocompromised and immunocompetent patients over the age of 75 years diagnosed with locally advanced or metastatic cSCC and treated with cemiplimab or pembrolizumab. The median duration of follow-up from cSCC diagnosis was 35.6 months, 82.9% of patients were male, and the median age was 83 years old. The median progression-free survival was 8.94 months. The incidence of treatment-related adverse events was 85.6%, the majority of which were grades 1 or 2. The disease control rate was 91.4%, the complete response rate was 17.1%, the partial response rate was 51.4%, the stable disease rate was 23%, and the progressive disease rate was 8.7%. Based on this study, cemiplimab and pembrolizumab for the treatment of locally advanced or metastatic cSCC in elderly, immunocompromised patients are efficacious, with acceptable safety profiles.
皮肤鳞状细胞癌（cSCC）是第二常见的皮肤癌类型，衰老和长期紫外线暴露是该病的主要诱因。西米普利单抗和帕博利珠单抗近期获准用于治疗局部晚期和转移性cSCC——这类情况无法通过手术切除和/或放疗治愈。尽管临床试验结果令人鼓舞，但这些研究未纳入免疫功能低下老年患者。本研究纳入了所有75岁以上、诊断为局部晚期或转移性cSCC并接受西米普利单抗或帕博利珠单抗治疗的免疫功能低下及免疫功能正常患者。从cSCC诊断起的中位随访时间为35.6个月，82.9%的患者为男性，中位年龄83岁。中位无进展生存期为8.94个月。治疗相关不良事件发生率为85.6%，其中大部分为1级或2级。疾病控制率达91.4%，完全缓解率17.1%，部分缓解率51.4%，疾病稳定率23%，疾病进展率8.7%。本研究显示，西米普利单抗和帕博利珠单抗在治疗老年免疫功能低下患者的局部晚期或转移性cSCC方面具有疗效，且安全性可接受。
肿瘤(癌症)患者之家